Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunization Programs | 21 | 2024 | 267 | 3.930 |
Why?
|
Cost-Benefit Analysis | 43 | 2024 | 5526 | 1.960 |
Why?
|
Developing Countries | 18 | 2021 | 2911 | 1.610 |
Why?
|
Vaccination | 17 | 2024 | 3426 | 1.600 |
Why?
|
Vaccines | 10 | 2024 | 841 | 1.260 |
Why?
|
Gross Domestic Product | 2 | 2017 | 77 | 1.060 |
Why?
|
Health Planning | 4 | 2023 | 233 | 1.050 |
Why?
|
Health Care Costs | 17 | 2022 | 3242 | 1.040 |
Why?
|
Health Services Administration | 2 | 2015 | 63 | 0.930 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2018 | 2047 | 0.780 |
Why?
|
Income | 6 | 2019 | 1874 | 0.720 |
Why?
|
Health Policy | 11 | 2023 | 2698 | 0.710 |
Why?
|
Hepatitis B | 2 | 2018 | 707 | 0.680 |
Why?
|
Health Resources | 5 | 2017 | 949 | 0.650 |
Why?
|
Infant Care | 2 | 2017 | 181 | 0.640 |
Why?
|
Value of Life | 2 | 2017 | 97 | 0.610 |
Why?
|
Policy Making | 3 | 2018 | 546 | 0.580 |
Why?
|
Papillomavirus Infections | 4 | 2018 | 1640 | 0.560 |
Why?
|
Papillomavirus Vaccines | 4 | 2017 | 496 | 0.560 |
Why?
|
Financial Management | 1 | 2018 | 161 | 0.530 |
Why?
|
Ketamine | 1 | 2022 | 525 | 0.530 |
Why?
|
Economics | 1 | 2017 | 141 | 0.530 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2015 | 2203 | 0.530 |
Why?
|
Licensure | 1 | 2017 | 128 | 0.520 |
Why?
|
Nonprescription Drugs | 1 | 2017 | 119 | 0.510 |
Why?
|
Capital Financing | 2 | 2015 | 58 | 0.510 |
Why?
|
Health Facilities | 5 | 2017 | 577 | 0.510 |
Why?
|
Resource Allocation | 1 | 2018 | 354 | 0.500 |
Why?
|
International Cooperation | 4 | 2018 | 1432 | 0.490 |
Why?
|
Malnutrition | 1 | 2021 | 629 | 0.480 |
Why?
|
HIV Infections | 17 | 2022 | 17533 | 0.480 |
Why?
|
Financial Support | 2 | 2016 | 116 | 0.480 |
Why?
|
Models, Economic | 7 | 2020 | 716 | 0.480 |
Why?
|
Medically Underserved Area | 1 | 2017 | 266 | 0.480 |
Why?
|
Anti-Retroviral Agents | 3 | 2022 | 1787 | 0.450 |
Why?
|
Mass Screening | 7 | 2019 | 5445 | 0.450 |
Why?
|
Honduras | 4 | 2017 | 39 | 0.430 |
Why?
|
India | 8 | 2024 | 2334 | 0.420 |
Why?
|
Maternal Health Services | 2 | 2022 | 472 | 0.400 |
Why?
|
Hepatitis B Vaccines | 1 | 2013 | 178 | 0.380 |
Why?
|
Mass Vaccination | 1 | 2013 | 111 | 0.380 |
Why?
|
Anesthesia | 1 | 2022 | 1590 | 0.370 |
Why?
|
Health Promotion | 3 | 2018 | 2208 | 0.370 |
Why?
|
Anti-HIV Agents | 7 | 2020 | 4559 | 0.350 |
Why?
|
Life Expectancy | 1 | 2017 | 1247 | 0.340 |
Why?
|
Investments | 1 | 2011 | 148 | 0.340 |
Why?
|
Quality-Adjusted Life Years | 8 | 2021 | 1737 | 0.330 |
Why?
|
Immunoglobulins | 1 | 2013 | 852 | 0.330 |
Why?
|
Models, Statistical | 4 | 2017 | 5089 | 0.300 |
Why?
|
Hepatitis C | 1 | 2018 | 1597 | 0.290 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2013 | 1354 | 0.290 |
Why?
|
Public Health | 3 | 2017 | 2680 | 0.280 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2013 | 2187 | 0.280 |
Why?
|
Health Expenditures | 3 | 2016 | 2387 | 0.260 |
Why?
|
Humans | 84 | 2024 | 765956 | 0.250 |
Why?
|
Burkina Faso | 2 | 2021 | 88 | 0.230 |
Why?
|
Immunologic Factors | 1 | 2013 | 1587 | 0.220 |
Why?
|
CD4 Lymphocyte Count | 4 | 2021 | 2587 | 0.220 |
Why?
|
Models, Theoretical | 7 | 2021 | 3564 | 0.220 |
Why?
|
South Africa | 6 | 2021 | 1867 | 0.210 |
Why?
|
Taxes | 2 | 2015 | 219 | 0.210 |
Why?
|
Infant | 9 | 2024 | 36385 | 0.210 |
Why?
|
Immunization Schedule | 1 | 2024 | 228 | 0.210 |
Why?
|
Subacute Care | 1 | 2024 | 184 | 0.190 |
Why?
|
Prisoners | 1 | 2005 | 316 | 0.180 |
Why?
|
Moldova | 2 | 2017 | 14 | 0.180 |
Why?
|
Antitubercular Agents | 2 | 2006 | 1384 | 0.180 |
Why?
|
Drug Costs | 3 | 2017 | 1193 | 0.180 |
Why?
|
Bacterial Infections | 2 | 2021 | 1387 | 0.180 |
Why?
|
Ghana | 2 | 2022 | 333 | 0.170 |
Why?
|
Zambia | 2 | 2019 | 273 | 0.170 |
Why?
|
Costs and Cost Analysis | 4 | 2020 | 1668 | 0.170 |
Why?
|
Communicable Diseases | 2 | 2021 | 874 | 0.170 |
Why?
|
Kenya | 1 | 2022 | 758 | 0.170 |
Why?
|
Child | 18 | 2022 | 80563 | 0.160 |
Why?
|
Point-of-Care Systems | 3 | 2019 | 1217 | 0.160 |
Why?
|
Decision Support Techniques | 4 | 2015 | 2003 | 0.160 |
Why?
|
Infant, Newborn | 6 | 2022 | 26349 | 0.160 |
Why?
|
Bacterial Vaccines | 1 | 2021 | 400 | 0.160 |
Why?
|
Food | 2 | 2021 | 764 | 0.160 |
Why?
|
Botswana | 1 | 2022 | 1057 | 0.160 |
Why?
|
Communicable Disease Control | 2 | 2021 | 856 | 0.150 |
Why?
|
Infection Control | 2 | 2016 | 983 | 0.150 |
Why?
|
Africa South of the Sahara | 3 | 2017 | 751 | 0.150 |
Why?
|
Refrigeration | 2 | 2015 | 27 | 0.150 |
Why?
|
Program Development | 2 | 2023 | 1295 | 0.150 |
Why?
|
Politics | 2 | 2022 | 822 | 0.150 |
Why?
|
Benin | 1 | 2017 | 12 | 0.150 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2006 | 942 | 0.150 |
Why?
|
Child, Preschool | 10 | 2024 | 42500 | 0.150 |
Why?
|
Osteotomy | 2 | 1994 | 833 | 0.150 |
Why?
|
Child Care | 2 | 2016 | 126 | 0.150 |
Why?
|
Edema | 1 | 2021 | 760 | 0.140 |
Why?
|
Health Services Needs and Demand | 2 | 2016 | 1406 | 0.140 |
Why?
|
Home Care Services | 1 | 2024 | 660 | 0.140 |
Why?
|
Meningococcal Vaccines | 1 | 2018 | 96 | 0.140 |
Why?
|
Decision Making, Computer-Assisted | 1 | 2017 | 147 | 0.140 |
Why?
|
Hallux Valgus | 2 | 1994 | 67 | 0.130 |
Why?
|
Cross Infection | 2 | 2016 | 1427 | 0.130 |
Why?
|
Patient Preference | 1 | 2024 | 952 | 0.130 |
Why?
|
Measles | 1 | 2018 | 180 | 0.130 |
Why?
|
Growth | 1 | 2017 | 365 | 0.130 |
Why?
|
Negotiating | 1 | 2017 | 152 | 0.130 |
Why?
|
Body Weight | 2 | 2017 | 4622 | 0.120 |
Why?
|
Chlamydia trachomatis | 1 | 2017 | 240 | 0.120 |
Why?
|
Acinetobacter Infections | 1 | 2015 | 74 | 0.120 |
Why?
|
Physical Education and Training | 1 | 2015 | 102 | 0.120 |
Why?
|
Female | 35 | 2024 | 396101 | 0.120 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2016 | 592 | 0.120 |
Why?
|
Efficiency, Organizational | 1 | 2019 | 697 | 0.120 |
Why?
|
Obesity | 5 | 2017 | 13075 | 0.120 |
Why?
|
World Health Organization | 3 | 2022 | 1328 | 0.110 |
Why?
|
Comprehensive Health Care | 1 | 2015 | 123 | 0.110 |
Why?
|
Policy | 1 | 2018 | 511 | 0.110 |
Why?
|
Drug Dosage Calculations | 1 | 2014 | 116 | 0.110 |
Why?
|
Tuberculosis | 3 | 2019 | 2012 | 0.110 |
Why?
|
Cesarean Section | 1 | 2022 | 1431 | 0.110 |
Why?
|
Bayes Theorem | 2 | 2020 | 2354 | 0.100 |
Why?
|
Beverages | 2 | 2015 | 819 | 0.100 |
Why?
|
Hepatitis B e Antigens | 1 | 2013 | 135 | 0.100 |
Why?
|
Sweetening Agents | 1 | 2015 | 291 | 0.100 |
Why?
|
Adult | 23 | 2021 | 223038 | 0.100 |
Why?
|
Uganda | 1 | 2017 | 1353 | 0.100 |
Why?
|
Nigeria | 2 | 2012 | 782 | 0.100 |
Why?
|
Financing, Government | 1 | 2016 | 473 | 0.100 |
Why?
|
Mortality | 2 | 2021 | 2904 | 0.100 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2019 | 838 | 0.100 |
Why?
|
Disease Outbreaks | 2 | 2015 | 1759 | 0.100 |
Why?
|
Drugs, Generic | 1 | 2017 | 456 | 0.100 |
Why?
|
Exercise Tolerance | 1 | 2017 | 841 | 0.100 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2013 | 294 | 0.100 |
Why?
|
Drug Resistance, Bacterial | 1 | 2019 | 1069 | 0.100 |
Why?
|
Commerce | 1 | 2017 | 611 | 0.100 |
Why?
|
Pregnancy | 5 | 2022 | 30258 | 0.100 |
Why?
|
Taiwan | 1 | 2013 | 521 | 0.090 |
Why?
|
School Health Services | 1 | 2015 | 387 | 0.090 |
Why?
|
Diarrhea | 1 | 2018 | 1316 | 0.090 |
Why?
|
Drug Monitoring | 1 | 2017 | 962 | 0.090 |
Why?
|
Body Height | 1 | 2017 | 1562 | 0.090 |
Why?
|
Histological Techniques | 1 | 2011 | 193 | 0.090 |
Why?
|
Adolescent | 15 | 2021 | 88832 | 0.090 |
Why?
|
Lipopolysaccharides | 1 | 2019 | 2216 | 0.090 |
Why?
|
Decision Trees | 1 | 2013 | 509 | 0.090 |
Why?
|
Brazil | 1 | 2015 | 1248 | 0.090 |
Why?
|
Metatarsal Bones | 1 | 1992 | 111 | 0.090 |
Why?
|
Sexually Transmitted Diseases | 1 | 2017 | 667 | 0.090 |
Why?
|
Delivery, Obstetric | 2 | 2022 | 946 | 0.090 |
Why?
|
Body Mass Index | 6 | 2017 | 13039 | 0.090 |
Why?
|
Tendons | 1 | 1994 | 555 | 0.090 |
Why?
|
Disease Transmission, Infectious | 2 | 2006 | 560 | 0.090 |
Why?
|
Catheters | 1 | 2013 | 426 | 0.080 |
Why?
|
Osteonecrosis | 1 | 1992 | 230 | 0.080 |
Why?
|
Joints | 1 | 2011 | 321 | 0.080 |
Why?
|
Research | 1 | 2018 | 1975 | 0.080 |
Why?
|
Checklist | 2 | 2022 | 848 | 0.080 |
Why?
|
Cleft Lip | 1 | 2015 | 512 | 0.080 |
Why?
|
Cleft Palate | 1 | 2015 | 592 | 0.080 |
Why?
|
Carrier State | 1 | 2013 | 529 | 0.080 |
Why?
|
Dyspnea | 1 | 2017 | 1352 | 0.080 |
Why?
|
Surgical Sponges | 1 | 2009 | 40 | 0.080 |
Why?
|
Directly Observed Therapy | 2 | 2006 | 139 | 0.080 |
Why?
|
Health Services Accessibility | 3 | 2017 | 5506 | 0.080 |
Why?
|
Community Health Services | 1 | 2013 | 657 | 0.080 |
Why?
|
Cardiology Service, Hospital | 1 | 2010 | 242 | 0.080 |
Why?
|
Decision Making | 3 | 2022 | 3965 | 0.070 |
Why?
|
Viral Load | 1 | 2017 | 3386 | 0.070 |
Why?
|
Arthroplasty, Replacement | 1 | 2011 | 314 | 0.070 |
Why?
|
Regression Analysis | 1 | 2017 | 6321 | 0.070 |
Why?
|
Self Report | 2 | 2016 | 3771 | 0.070 |
Why?
|
Male | 26 | 2024 | 363691 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5369 | 0.070 |
Why?
|
Women's Health | 1 | 2017 | 2084 | 0.070 |
Why?
|
Young Adult | 11 | 2021 | 59886 | 0.070 |
Why?
|
Models, Biological | 2 | 2021 | 9443 | 0.070 |
Why?
|
Health Personnel | 3 | 2017 | 3390 | 0.070 |
Why?
|
Organizational Innovation | 1 | 2010 | 541 | 0.070 |
Why?
|
United States | 14 | 2024 | 72898 | 0.070 |
Why?
|
Pneumonia | 1 | 2018 | 2157 | 0.070 |
Why?
|
Sputum | 2 | 2019 | 513 | 0.070 |
Why?
|
Critical Illness | 2 | 2016 | 2744 | 0.070 |
Why?
|
Mozambique | 2 | 2017 | 55 | 0.070 |
Why?
|
Surgical Procedures, Operative | 2 | 2016 | 1941 | 0.060 |
Why?
|
Hypertension, Pulmonary | 1 | 2017 | 1604 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 790 | 0.060 |
Why?
|
Middle Aged | 15 | 2024 | 223004 | 0.060 |
Why?
|
Cost Savings | 1 | 2010 | 904 | 0.060 |
Why?
|
Employment | 1 | 2011 | 1106 | 0.060 |
Why?
|
Probability | 2 | 2013 | 2475 | 0.060 |
Why?
|
Safety Management | 1 | 2010 | 763 | 0.060 |
Why?
|
Foreign Bodies | 1 | 2009 | 402 | 0.060 |
Why?
|
Budgets | 1 | 2006 | 232 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7836 | 0.060 |
Why?
|
Connecticut | 1 | 2005 | 365 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2012 | 953 | 0.060 |
Why?
|
Thrombolytic Therapy | 1 | 2013 | 2059 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3236 | 0.060 |
Why?
|
Caribbean Region | 2 | 2015 | 193 | 0.060 |
Why?
|
Venous Thrombosis | 1 | 2013 | 1327 | 0.050 |
Why?
|
Peru | 1 | 2006 | 887 | 0.050 |
Why?
|
Latin America | 2 | 2015 | 416 | 0.050 |
Why?
|
Age Factors | 2 | 2016 | 18380 | 0.050 |
Why?
|
Homosexuality, Male | 2 | 2021 | 1342 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 3685 | 0.050 |
Why?
|
Pan American Health Organization | 2 | 2013 | 5 | 0.050 |
Why?
|
Television | 2 | 2015 | 409 | 0.050 |
Why?
|
Mycobacterium tuberculosis | 2 | 2019 | 1917 | 0.050 |
Why?
|
Intraoperative Complications | 1 | 2009 | 1162 | 0.050 |
Why?
|
Papillomaviridae | 2 | 2018 | 1141 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8701 | 0.050 |
Why?
|
Hospitals, Pediatric | 1 | 2010 | 1846 | 0.050 |
Why?
|
Housing | 1 | 2005 | 683 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2010 | 2172 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2017 | 4873 | 0.040 |
Why?
|
Treatment Failure | 1 | 2006 | 2652 | 0.040 |
Why?
|
Exercise | 1 | 2016 | 5937 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 1 | 2006 | 1971 | 0.040 |
Why?
|
Skilled Nursing Facilities | 1 | 2024 | 410 | 0.040 |
Why?
|
Risk | 3 | 2017 | 9591 | 0.040 |
Why?
|
Software | 1 | 2013 | 4462 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2021 | 81515 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2013 | 14652 | 0.040 |
Why?
|
Parturition | 1 | 2022 | 453 | 0.040 |
Why?
|
Malawi | 1 | 2019 | 315 | 0.040 |
Why?
|
Public Sector | 1 | 2019 | 264 | 0.040 |
Why?
|
Prevalence | 4 | 2017 | 15839 | 0.040 |
Why?
|
Rifampin | 1 | 2019 | 351 | 0.030 |
Why?
|
Hospitals | 1 | 2010 | 3888 | 0.030 |
Why?
|
Treponema pallidum | 1 | 2017 | 48 | 0.030 |
Why?
|
Aged | 7 | 2024 | 171114 | 0.030 |
Why?
|
Trichomonas vaginalis | 1 | 2017 | 70 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2019 | 335 | 0.030 |
Why?
|
Vaccines, Conjugate | 1 | 2018 | 334 | 0.030 |
Why?
|
Immunization | 1 | 2020 | 1219 | 0.030 |
Why?
|
Adrenal Cortex | 1 | 1996 | 134 | 0.030 |
Why?
|
Guidelines as Topic | 2 | 2014 | 1394 | 0.030 |
Why?
|
Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
Acinetobacter | 1 | 2015 | 39 | 0.030 |
Why?
|
Herpesvirus 2, Human | 1 | 2017 | 191 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2005 | 2193 | 0.030 |
Why?
|
Incidence | 4 | 2018 | 21480 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 452 | 0.030 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2016 | 212 | 0.030 |
Why?
|
Time Factors | 2 | 2017 | 40065 | 0.030 |
Why?
|
Renin | 1 | 1996 | 647 | 0.030 |
Why?
|
Microscopy | 1 | 2019 | 901 | 0.030 |
Why?
|
Neisseria gonorrhoeae | 1 | 2017 | 248 | 0.030 |
Why?
|
Computer Simulation | 2 | 2019 | 6255 | 0.030 |
Why?
|
Heart Defects, Congenital | 1 | 2010 | 4698 | 0.030 |
Why?
|
Chlamydia Infections | 1 | 2017 | 364 | 0.030 |
Why?
|
Altruism | 1 | 2015 | 211 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2018 | 1238 | 0.030 |
Why?
|
Regional Health Planning | 1 | 2013 | 95 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 11840 | 0.030 |
Why?
|
Rotavirus Vaccines | 1 | 2013 | 62 | 0.030 |
Why?
|
Colombia | 1 | 2013 | 287 | 0.020 |
Why?
|
Radiography | 2 | 1994 | 6919 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 967 | 0.020 |
Why?
|
Caregivers | 1 | 2024 | 2307 | 0.020 |
Why?
|
Treatment Outcome | 4 | 2017 | 65189 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2019 | 2739 | 0.020 |
Why?
|
Prisons | 1 | 2013 | 178 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1641 | 0.020 |
Why?
|
Capacity Building | 1 | 2013 | 266 | 0.020 |
Why?
|
Reference Values | 1 | 2017 | 4908 | 0.020 |
Why?
|
Blood Coagulation Disorders | 1 | 2013 | 349 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2015 | 59488 | 0.020 |
Why?
|
Markov Chains | 1 | 2013 | 968 | 0.020 |
Why?
|
Pneumococcal Vaccines | 1 | 2013 | 414 | 0.020 |
Why?
|
Family Planning Services | 1 | 2012 | 278 | 0.020 |
Why?
|
Epidemics | 1 | 2015 | 514 | 0.020 |
Why?
|
Urban Population | 1 | 2017 | 2040 | 0.020 |
Why?
|
Exercise Test | 1 | 2017 | 2180 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2017 | 39194 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2016 | 1741 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 1992 | 1478 | 0.020 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2011 | 390 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 3138 | 0.020 |
Why?
|
Universities | 1 | 2013 | 998 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 1992 | 1978 | 0.020 |
Why?
|
Schools | 1 | 2016 | 1492 | 0.020 |
Why?
|
Isotope Labeling | 1 | 2009 | 389 | 0.020 |
Why?
|
Random Allocation | 1 | 1992 | 2395 | 0.020 |
Why?
|
Patient Care Management | 1 | 2010 | 303 | 0.020 |
Why?
|
Rural Population | 1 | 2017 | 2317 | 0.020 |
Why?
|
Critical Pathways | 1 | 2010 | 475 | 0.020 |
Why?
|
Asia, Southeastern | 1 | 2006 | 115 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2017 | 20125 | 0.020 |
Why?
|
Patient Participation | 1 | 2015 | 1454 | 0.020 |
Why?
|
Obesity, Morbid | 1 | 2016 | 1292 | 0.010 |
Why?
|
Program Evaluation | 1 | 2013 | 2499 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2780 | 0.010 |
Why?
|
Mining | 1 | 2005 | 93 | 0.010 |
Why?
|
Survival Rate | 1 | 2018 | 12795 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3853 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2192 | 0.010 |
Why?
|
Mitochondria | 1 | 1996 | 3673 | 0.010 |
Why?
|
Transients and Migrants | 1 | 2005 | 170 | 0.010 |
Why?
|
Cohort Studies | 2 | 2015 | 41647 | 0.010 |
Why?
|
Parents | 1 | 2016 | 3592 | 0.010 |
Why?
|
Poverty | 1 | 2014 | 2714 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 1994 | 3475 | 0.010 |
Why?
|
Data Collection | 1 | 2010 | 3318 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14749 | 0.010 |
Why?
|
Drug Design | 1 | 2006 | 1042 | 0.010 |
Why?
|
Recurrence | 1 | 2013 | 8501 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2006 | 1472 | 0.010 |
Why?
|
Pilot Projects | 1 | 2013 | 8733 | 0.010 |
Why?
|
Biomedical Research | 1 | 2015 | 3458 | 0.010 |
Why?
|
Hospitalization | 1 | 2019 | 10808 | 0.010 |
Why?
|
Prospective Studies | 2 | 1994 | 54806 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 4850 | 0.010 |
Why?
|
Patient Selection | 1 | 2010 | 4255 | 0.010 |
Why?
|
Anticoagulants | 1 | 2013 | 4862 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9338 | 0.010 |
Why?
|
Patient Compliance | 1 | 2006 | 2692 | 0.010 |
Why?
|
Contrast Media | 1 | 2009 | 5329 | 0.010 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 1996 | 323 | 0.010 |
Why?
|
Family | 1 | 2005 | 3209 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1996 | 2548 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7425 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15398 | 0.010 |
Why?
|
Postoperative Complications | 1 | 1994 | 15747 | 0.010 |
Why?
|
Risk Factors | 2 | 2005 | 74836 | 0.010 |
Why?
|
Quality of Life | 1 | 2013 | 13461 | 0.010 |
Why?
|
Nephrectomy | 1 | 1996 | 927 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 1996 | 8102 | 0.000 |
Why?
|
Kidney | 1 | 1996 | 7066 | 0.000 |
Why?
|
Rats | 1 | 1996 | 23707 | 0.000 |
Why?
|
Animals | 1 | 1996 | 168759 | 0.000 |
Why?
|